Anti-cytokine therapy and plasma DNA in patients with rheumatoid arthritis

ConclusionTreatment with bDMARDs decreases plasma ecDNA of both nuclear and mitochondrial origin. Dynamics of ecDNA is slower than dynamics of standard clinical markers. Therefore, it is likely to be not useful for monitoring of the disease progress, at least for RA.

Source: Rheumatology International - July 13, 2018 Category: Rheumatology Source Type: research